Investigator-initiated Phase II Study of Pembrolizumab Immunological Response Evaluation
This is a phase 2 study whose main purpose is to evaluate gene changes and immune biomarkers
in patients with solid tumours during treatment with pembrolizumab and in relation to
response to treatment.
Pembrolizumab is a monoclonal antibody that is designed to block a protein called programmed
cell death 1 ligand 1 (PD-L1) which will allow the body's immune system to kill the cancer
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society